introduction
Quantum-First Architecture
Proprietary quantum search explores chemical space far beyond classical heuristics, while HPC-trained models learn the subtle signatures in clinical images and multi-omics matrices that conventional tools miss. The result: deeper exploration, faster iteration, and signals that translate from bench to bedside.
Integrated Discovery Platform
A single spine unifies three pillars; molecular simulation, radiomic feature discovery, and multi-omics pathway mapping, so insights flow across modalities instead of living in silos. One infrastructure, shared security and validation, cloud or on-prem, PACS/EHR-ready.
Who we serve
01
Hospitals
Plug into your existing PACS—no rip-and-replace. Radiomics overlays and clinician-ready reports surface earlier flags so teams move faster and readmissions drop.
02
Pharmaceuticals
Run CTSim™' generate–test–refine loop to explore more space, then stratify cohorts with imaging and predict response sooner—de-risking trials from lead triage to study design.
03
Research
We believe in honesty and transparency in all aspects of our practice. From clear communication about your treatment options to ethical business practices, we strive to build trust with our patients.
Our Products
Redefining Quantum
“Internal pilots showed up to 90× faster imaging workflows and 48× faster genomic processing, surfacing candidates missed by conventional screens.”
Dr. Ahmed Fadiel, MS, PhD
Founder Quantum Dance
Benefits + Features
We design for outcomes, not hype. A hybrid quantum–classical stack powers CTSim™, QuantumVision™, and QuantumOmix™ so teams see earlier signal, make clearer decisions, and move from discovery to decision faster.
Hybrid by design
Quantum accelerates complex search and simulation while HPC orchestrates training and inference at scale, seamlessly plugging into lab and clinical workflows for reliable, real-world deployments.
Clinical-grade from day one
Security, encryption, access controls, and data-residency options align with GDPR and HIPAA expectations, preserving privacy & auditability without slowing teams or breaking existing processes.
End-to-end learning loop
Three platforms feed each other; molecule to biomarker to pathway, so insights compound across CTSim™, QuantumVision™, and QuantumOmix™, improving prioritization and reducing waste.
Measurable signal, earlier
Radiomics and multi-omics surface features conventional reads miss, raising sensitivity and confidence so teams can prioritize sooner design smarter trials, and focus effort where impact matters.
Interoperable, not isolated
Works with PACS, LIMS, and data lakes already in place; bring your models and assays, then export clean outputs into downstream tools so scientists and clinicians act without friction.
Our Progress
1
CTSim™ evolution
From early quantum docking prototypes to CTSim™ v3 with hybrid quantum‑classical pipelines that screen large chemical space and prioritize high‑affinity candidates with greater precision.
2
QuantumVision validation
Progressed from single‑site experiments to multi‑site radiomics studies, producing robust imaging biomarkers and model reproducibility across scanners and protocols.
3
QuantumOmix at scale
Advanced from small cohorts to multi‑omics graphs handling large datasets, mapping variant to pathway relationships and enabling target discovery and patient stratification.
4
Compliance and reliability
Moved from research sandboxes to enterprise deployments with audit trails, access controls, and HIPAA/GDPR‑ready data handling across imaging and omics workflows.
5
Partnered deployments
Expanded from proof‑of‑concepts to active collaborations with pharma and research hospitals, delivering APIs that integrate with LIMS, EHR, and PACS for end‑to‑end workflows.
Our Performance
GDPR, CCPA & EUAI Compliant
HIPAA Compliant
Frequently Asked Questions
How is quantum different from classical methods?
Our hybrid quantum-classical architecture explores chemical space exponentially faster. CTSim's quantum algorithms simulate millions of molecular interactions simultaneously, while classical tools process sequentially. Results: promising drug candidates identified in days versus months, with superior binding affinity predictions and early liability detection.